Literature DB >> 15479822

Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype.

Ingrid Karlsson1, Liselotte Antonsson, Yu Shi, Monica Oberg, Anders Karlsson, Jan Albert, Björn Olde, Christer Owman, Marianne Jansson, Eva Maria Fenyö.   

Abstract

The evolution of human immunodeficiency virus type 1 (HIV-1) coreceptor use has been described as the acquisition of CXCR4 use linked to accelerated disease progression. However, CXCR4-using virus can be isolated only from approximately one-half of individuals with progressive HIV-1 disease. The other half continue to yield only CCR5-using viruses (R5 phenotype) throughout the course of disease. In the present work, the use of receptor chimeras between CCR5 and CXCR4 allowed us to study the evolution of HIV-1 with the R5 phenotype, which was not revealed by studies of wild-type coreceptor use. All together, 246 isolates (173 with the R5 phenotype) from 31 individuals were tested for their ability to infect cells through receptor chimeras. R5(narrow) virus was able to use only wild-type CCR5, whereas R5(broad(1)) to R5(broad(3)) viruses were able to use one to three chimeric receptors, respectively. Broad use of chimeric receptors was interpreted as an increased flexibility in the mode of receptor use. R5(broad) isolates showed higher infectivity in cells expressing wild-type CCR5 than R5(narrow) isolates. Also, the increased flexibility of R5(broad) isolates was concomitant with a lower sensitivity to inhibition by the CC chemokine RANTES. Our results indicate a close relationship between HIV-1 phenotypic changes and the pathogenic process, since the mode and efficiency of CCR5 use as well as the decrease in the RANTES sensitivities of isolated viruses are significantly correlated with CD4(+)-T-cell decline in a patient. One possible explanation is that ligand competition at the CCR5 receptor or changed CCR5 availability may shape the outcome of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479822      PMCID: PMC523262          DOI: 10.1128/JVI.78.21.11807-11815.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1

Authors: 
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

2.  HIV-1 disease progression in women: role of the viral phenotype of the HIV-positive steady partner.

Authors:  J R Fiore; G Buccoliero; P Pezzotti; G Rezza; A Saracino; G Pastore; E M Fenyo; G Angarano
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

3.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

4.  A new classification for HIV-1.

Authors:  E A Berger; R W Doms; E M Fenyö; B T Korber; D R Littman; J P Moore; Q J Sattentau; H Schuitemaker; J Sodroski; R A Weiss
Journal:  Nature       Date:  1998-01-15       Impact factor: 49.962

5.  Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion.

Authors:  L Picard; G Simmons; C A Power; A Meyer; R A Weiss; P R Clapham
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  The biological phenotype of HIV-1 is usually retained during and after sexual transmission.

Authors:  J R Fiore; A Björndal; K A Peipke; M Di Stefano; G Angarano; G Pastore; H Gaines; E M Fenyö; J Albert
Journal:  Virology       Date:  1994-10       Impact factor: 3.616

7.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

Authors:  G Scarlatti; E Tresoldi; A Björndal; R Fredriksson; C Colognesi; H K Deng; M S Malnati; A Plebani; A G Siccardi; D R Littman; E M Fenyö; P Lusso
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

8.  Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection.

Authors:  Fransje A Koning; David Kwa; Brigitte Boeser-Nunnink; Jos Dekker; Jose Vingerhoed; Harry Hiemstra; Hanneke Schuitemaker
Journal:  J Infect Dis       Date:  2003-09-04       Impact factor: 5.226

9.  MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection.

Authors:  A Karlsson; K Parsmyr; E Sandström; E M Fenyö; J Albert
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

10.  Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics.

Authors:  V A Sundqvist; J Albert; E Ohlsson; J Hinkula; E M Fenyö; B Wahren
Journal:  J Med Virol       Date:  1989-11       Impact factor: 2.327

View more
  36 in total

1.  Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.

Authors:  Eric G Meissner; Vernon M Coffield; Lishan Su
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

2.  Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch.

Authors:  Mattias Mild; Joakim Esbjörnsson; Eva Maria Fenyö; Patrik Medstrand
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

3.  Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.

Authors:  Nicole Espy; Beatriz Pacheco; Joseph Sodroski
Journal:  Virology       Date:  2017-05-15       Impact factor: 3.616

4.  Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

Authors:  Zahra F Parker; Shilpa S Iyer; Craig B Wilen; Nicholas F Parrish; Kelechi C Chikere; Fang-Hua Lee; Chuka A Didigu; Reem Berro; Per Johan Klasse; Benhur Lee; John P Moore; George M Shaw; Beatrice H Hahn; Robert W Doms
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

5.  Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.

Authors:  Mariangela Cavarelli; Lara Mainetti; Angela Rosa Pignataro; Alba Bigoloni; Monica Tolazzi; Andrea Galli; Silvia Nozza; Antonella Castagna; Michela Sampaolo; Enzo Boeri; Gabriella Scarlatti
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12       Impact factor: 2.205

6.  Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue.

Authors:  Ingrid Karlsson; Jean-Charles Grivel; Silvia Sihui Chen; Anders Karlsson; Jan Albert; Eva Maria Fenyö; Leonid B Margolis
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.

Authors:  Ulf Karlsson; Liselotte Antonsson; Johanna Repits; Patrik Medstrand; Christer Owman; Karin Kidd-Ljunggren; Lars Hagberg; Bo Svennerholm; Marianne Jansson; Magnus Gisslén; Bengt Ljungberg
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

8.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.

Authors:  John C Tilton; Heather Amrine-Madsen; John L Miamidian; Kathryn M Kitrinos; Jennifer Pfaff; James F Demarest; Neelanjana Ray; Jerry L Jeffrey; Celia C Labranche; Robert W Doms
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

10.  Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.

Authors:  Behzad Etemad; Angela Fellows; Brenda Kwambana; Anupa Kamat; Yang Feng; Sandra Lee; Manish Sagar
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.